Answers are grounded in this paper and cite their sources.
Colorectal cancer (CRC) ranks among the leading causes of cancer-related mortality worldwide, yet the vast majority of metastatic cases, classified as proficient mismatch repair and microsatellite-stable(pMMR/MSS), derive little benefit from immune checkpoint inhibitors (ICIs). This primary resistance stems from convergent tumor-intrinsic alterations, including deficient antigen presentation, Wnt/β-catenin-driven T cell exclusion, and metabolic reprogramming, alongside microenvironmental barriers such as immunosuppressive myeloid cell infiltration, stromal exclusion, and gut microbiota dysbiosis. Here, we synthesize the multi-layered resistance mechanisms that render pMMR/MSS CRC refractory to immunotherapy and critically evaluate the expanding portfolio of combination strategies designed to overcome them. We categorize these approaches into eight domains: anti-angiogenic agents combined with ICIs, MAPK pathway inhibitors paired with immunotherapy, epigenetic modulators, next-generation immune checkpoint targets (LAG-3, TIM-3, TIGIT, CD47), stimulator of interferon genes agonists and oncolytic viruses, cellular therapies and bispecific antibodies, personalized neoantigen vaccines, and radiotherapy-immunotherapy combinations. Throughout, early-phase response signals are contrasted with the negative randomized trials IMblaze370 and LEAP-017, neither of which improved overall survival in pMMR/MSS disease. We further discuss biomarker-guided stratification frameworks integrating molecular profiling (BRAF, KRAS, HER2 status), circulating tumor DNA dynamics, stromal signatures, and microbiome composition, and summarize key clinical trials in a structured evidence table. We conclude by outlining key translational gaps: validated predictive biomarkers, optimized sequencing strategies, and rationally designed trial endpoints. By mapping the mechanistic rationale for each combinatorial approach onto the specific resistance circuitry it targets, this review provides a structured framework for advancing pMMR/MSS CRC toward clinically meaningful immunotherapy responses.
No takes yet. Share an insight, caveat, or question.
Liao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: